J Otolaryngol Ophthalmol Shandong Univ ›› 2018, Vol. 32 ›› Issue (5): 110-113.doi: 10.6040/j.issn.1673-3770.0.2018.034

Previous Articles     Next Articles

Diagnosis and treatment of thyroid-associated ophthalmopathy

ZHU Mingjuan1, XING Kai2, KANG Zefeng3, LIU Jian3   

  1. Changping District Hospital of Traditional Chinese Medicine, Beijing 102200, China;3. Eye Hospital of Chinese Academy of Traditional Chinese Medicine, Beijing 100040, China
  • Received:2018-01-15 Online:2018-09-20 Published:2018-09-20

Abstract: Thyroid-related ophthalmopathy is an organ-specific autoimmune disease associated with abnormal thyroid function. The extra-glandular ocular involvement affects the appearance of the patient; severe cases can present with diplopia, decreased vision, or even blindness. The pathogenesis is not yet fully understood, and the current clinical therapeutic approaches cannot cure or provide relief to all patients. Moreover, there are many clinical treatment methods. Histopathological examination of the ocular soft tissue and extra-ocular muscles shows some immune inflammatory response, but the exact pathogenesis of this disease is not clear. This article reviews the latest research on the clinical diagnosis and treatment of thyroid-related ophthalmopathy.

Key words: Research progress, Thyroid-associated ophthalmopathy, Clinical diagnosis

CLC Number: 

  • R777.1
[1] Henfelder AE. Pathogenesis of ophthalmopathy in autoimmune thyroid disease[J]. Rev Endocr Metab Disond, 2000, 1(1-2):87-95.
[2] 周慧芳, 范先群. 甲状腺相关性眼病的治疗进展[J]. 中国实用眼科杂志,2008,26(8):760-763.
[3] 明健, 魏锐利. 17-β雌二醇在TAO成纤维细胞氧化应激中的保护作用研究[D]. 上海:第二军医大学,2013.
[4] Stein JD, Childers D, Gupta S. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease[J]. Arch Ophthalmol, 2015, 3(133):290-293.
[5] 赵立全, 魏锐利. 细胞因子与眼眶成纤维细胞[J]. 中国实用眼科杂志,2010,28(7):685-688.
[6] Gianoukakis AG, Khadavi N, Smith TJ. Cytokines, Graves disease,and thyroid-associated ophthalmopathy[J]. Thyroid, 2008, 18(9):953-958.
[7] Pan D, Shin YH, Gopalakrishnan G, et al. Regulatory T cells in Graves’disease[J]. Clin Endocrinol, 2009, 71(4):587-593.
[8] 徐霁, 李华, 蔡春华, 等. 血清IL-17,IL-21与Graves眼病相关性研究[J]. 中国煤炭工业医学杂志,2017,4(20):424-426. XU Ji, LI Hua, CAI Chunhua, et al. Correlations between il-17, il-21 levels and graves ophthalmopathy[J]. Chin J Coal Indust Med, 2017, 4(20):424-426.
[9] Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy Versus sham irradiation in patients with mind Graveshtllalmathy[J]. J Clin Endorcrinol Metab, 2004, 89(1):15-20.
[10] Bahn RS. Thyrotropin receptor expression in orbital adipose connective tissues fron patients with thyroid-associated ophthalmopathy[J]. Thyroid, 2002, 12(3):193-195.
[11] Pritchard J, Han R, Horst N, et al. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves disease is mediated through the insulin-like growth factor I receptor pathway[J]. J Immunol, 2003, 170(12):6348-6354.
[12] Vanderpump MPJ, Tunbridge WMG, French JM, et al. The incidence of thyroid disorders in the community-a twenty-year follow-up of the Whickham survey[J]. Clin Endocrinol, 1995, 43(1):55-69.
[13] Khalilzadeh O, Noshad S, et al. Graves ophthalmopathy: a review of immunogenetics[J]. Curr Genomics, 2011, 12(8):564-575.
[14] Bartley GB, Fatourechi V, Kadrmas EF, et al. Long-term follow-up of Graves ophthalmopathy in an incidence cohort[J]. Ophthalmology, 1996, 103(6):958-962.
[15] 栾洁. 甲状腺相关眼病的诊治[J]. 铁道医学,2001,29(4):213-214.
[16] Phan TT, Sun L, Bay BH, et al. Dietary compounds inhibit proliferation and contraction of keloid and hypertrophic scar-derived fibroblasts in vitro: therapeutic implication for excessive scarring[J]. J Trauma, 2003, 54(6):1212-1224.
[17] 钱昱,李玉珍,梁文君,等. 甲状腺相关性眼病的研究及治疗进展[J]. 现代生物医学进展,2017,6(17):3195-3200. QIAN Yu, LI Yuzhen, LIANG Wenjun, et al. Progress and review in thyroid-associated ophthalmopathy[J]. Prog Modern Biom, 2017, 6(17):3195-3200.
[18] Scruggs RT, Black EH. Thyroid eye disease wirh significant levator involvement and ptosis:a case report[J]. Ophthal Plast Reconstr surg, 2015, 31(6):153-154.
[19] Menconi F, Marcocci C, Marino M. Diagnosis and classification of Graves’ disease[J]. Autoimmun Rev, 2014, 13(4-5):398-402.
[20] Van Dyk HJ. Orbital Graves disease:a modification of the “NO SPECS” classification[J]. Ophthalmology, 1981, 88(6):479-483.
[21] Bartalena L. Diagnosis management of Grave disease: a global overview[J]. Nat Rev Endocrinol, 2013, 9(12):723-734.
[22] 罗兴中,罗红强,杨海军. 甲状腺相关性眼病的研究现状[J]. 中国实用眼科杂志,2012,3(30):236-239.
[23] Phelps PO, Williams K. Thyroid eye disease for the primary care physician[J]. Dis Mon, 2014, 60(6):292-298.
[24] 郭剑津,刘超.Graves眼病的治疗:系统综述及meta分析[J]. 中华内分泌代谢杂志,2010,1(26):69-72.
[25] Henfelder AE. Pathsgenesis of ophthalmopathy in autoimmune thyroid disease[J]. Rev Endocr Metab Disond, 2000, 1(1-2):87-95.
[26] Naik VM, Naik MN, Goldberg RA, et al. DouglasRS. Immunopathogenesis of thyroid eye disease:emerging paradigms[J]. Surv Ophthalmol, 2010, 55(3):215-226.
[27] Stein JD, Kim DS, Niziol LM, et al. Differences in rates of glaucoma among Asian Americans and other racial groups[J]. Ophthalmology, 2011, 118(6):1031-1037.
[28] 左新河,牧亚峰. 从络病理论探析甲状腺相关性眼病的辨治[J]. 湖北中医杂志,2017,39(10):31-33.
[29] 王慧琴,邵迎新,刘文. 中西医结合治疗甲状腺相关性眼病[J]. 中华现代中西医杂志,2005,14(11):996.
[30] 顾明君,刘志民,朱莉,等. 奥曲肽和泼尼松治疗甲状腺相关性眼病的随机对照研究[J]. 第二军医大学学报,2002,23(5):540-543. GU Mingjun, LIU Zhimin, ZHU Li, et al. Randomized control trial of subcutaneous octreotide and oral prednisone in treatment of thyroid eye disease[J]. Acad J Sec Mil Med Univ, 2002, 23(5):540-543.
[31] 肖屏风. 中西医结合治疗甲状腺相关眼病疗效观察[J]. 临床医学进程,2009,18(7):530,544.
[32] Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves orbitopathy(EUGOGO)on management of Graves orbitopathy[J]. Thyroid, 2008, 18(3):333-346.
[33] 许薇薇,程金伟,蔡季平,等. Graves眼病治疗途径的现况及展望[J]. 中国实用眼科杂志,2007,25(8):823-825.
[34] 朱本章,朱江,乔文颖. Graves’眼病的诊断和治疗进展[J]. 内科急危重症杂志,2002,8(1):40-43.
[35] 李东豪,邱红红,张金山,等. 生长抑素治疗甲状腺相关性眼病的疗效分析[J]. 中国实用眼科杂志,2009,27(12):1372-1373. LI Donghao, QIU Honghong, ZHANG Jinshan, et al. Treatment for thyriod associated ophthalmopathy with Octreotide[J]. Chin J Pract Ophthalmol, 2009, 27(12):1372-1373.
[36] 王宇鹰,王养忠. 局部注射治疗甲状腺相关眼病32例报告[J]. 实用诊断与治疗杂志,2007,21(9):709-710.
[37] Newman-Casey PA, Talwar N, Nan B, et al. The relationship between components of metabolic syndrome and open-angle glaucoma[J]. Ophthalmology, 2011, 118(7):1318-1326.
[38] 田蓉,匡安仁,秦卫仕,等. 99Tc-MDP与免疫抑制疗法治疗Grave’眼病的对比研究[J]. 中华核医学杂志,2000,20(6):250-253.
[39] Ponto KA, Kanitz M, Olivo PD, et al. Clinical relevance of thyroid-stimulating immunoglobulins in graves’ophthalmopathy[J]. Ophthalmology,2011,118(11):2279-2285.
[40] Lytton SD, Ponto KA, Kanitz M, et al. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves’ orbitopathy[J]. J Clin Endocrinol Metab, 2010, 95(5):2123-2131.
[41] 王毅,赵海萍,苏帆,等. 切除眼眶深外侧和内侧骨壁的减压术治疗甲状腺相关眼病二例[J]. 中华眼科杂志,2010,46(9):846-848.
[42] Stan MN, Garrity JA, Bahn RS. The evaluation and treatment of graves ophthalmopathy[J]. Med Clin North Am, 2012, 96(2):311-328.
[43] Bartalena L, Baldeschi L, et al. The 2016 European Thyriod Association/European group on Graves Orbitopathy Guidelines for the Management of Graves orbitopathy[J]. Eur Thyroid J, 2016, 5(1):9-26.
[44] Marcocci C, Marino M. Treatment of mild, moderate-to-severe and very severe Graves orbitopathy[J]. Best Pract Res Clin Endocrinol Metab, 2012, 26(3):325-337.
[45] Tallstedt L, Lundell G, Blomgren H, et al. Does early administration of thyroxine reduce the development of Graves’ ophthalmopathy after radioiodine treatment?[J]. Eur J Endocrinol, 1994, 130(5):494-497.
[46] Kung AW, Yau CC, Cheng A. The incidence of ophthalmopathy after radioiodine therapy for Graves’ disease: prognostic factors and the role of methimazole[J]. J Clin Endocrinol Metab, 1994, 79(2):542-546.
[47] Huang CC, Chan WL, Chen YC, et al. Statin use in patients with asthma: a nationwide population-based study[J]. Eur J ClinInvest, 2011, 41(5):507-512.
[48] Semb AG, HolmeI, Kvien TK, et al. Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering(IDEAL)trial[J]. Rheumatology, 2011, 50(2): 324-329.
[49] McCarey DW, McInnesI B, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis(TARA): double-blind, randomised placebo-controlled trial[J]. Lancet, 2004, 363(9426):2015-2021.
[50] Hu Y, Tong G, Xu W, et al. Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis[J]. Diab Vasc Dis Res, 2009, 6(4):262-268.
[51] Marcocci C, Kahaly GJ, Krassas GE, et al. Selenium and the course of mild Graves orbitopathy[J]. N EngI J Med, 2011, 364(20):1920-1931.
[52] Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms[J]. Nat Rev Drug Discov, 2005, 4(12):977-987.
[1] WEI Chao, ZHANG Han. Multifocal intraocular lens: progress in clinical application. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(4): 29-35.
[2] ZHANG Ruxin. Prospect and progress of allergic rhinitis. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(4): 3-6.
[3] LIU Wen. Relationship of near-work-induced  transient myopia and myopia development [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2012, 26(3): 83-85.
Full text



No Suggested Reading articles found!